The Science Behind Our Approach
Every treatment we offer at Seaside Ketamine is grounded in peer-reviewed research and clinical evidence. Our protocols are built on published data, real-world outcomes, and emerging discoveries in psychiatry, neuroscience, and metabolic health.
Evidence Navigation
Ketamine for Depression
Ketamine for Anxiety & PTSD
Chronic Pain & Migraine
Metabolic Psychiatry
Neuroplasticity & Integration
Why We Lead With Evidence
Mental health care has been dominated by a trial-and-error model for decades. Patients are prescribed medications sequentially, often waiting weeks or months to determine whether a treatment works.
At Seaside Ketamine, we approach treatment differently. We believe that understanding the biological mechanisms behind depression, trauma, chronic pain, and metabolic dysfunction leads to better clinical decisions and more durable outcomes.
Below, we summarize key findings across the major areas of our practice. We include citations from peer-reviewed journals and leading academic institutions.
This page is not intended as medical advice. It is intended to help you make an informed decision about your care.
Ketamine for Depression: What the Research Shows
Depression affects an estimated 332 million people worldwide, and roughly one-third of individuals do not respond adequately to traditional antidepressants.
Ketamine has emerged as one of the most significant advances in depression treatment in decades.
Key Research Findings
Meta-analyses including over 25 randomized controlled trials confirm that ketamine produces large antidepressant effects (Cohen’s d ≥ 1.0) in treatment-resistant depression, with maximum symptom reduction observed at 24 hours post-infusion.
Source: Molecular Psychiatry (2022), pooled patient-level meta-analysis (n=809).
A 2023 systematic review and meta-analysis found that adequate-dose ketamine formulations consistently outperform placebo for depression, with higher doses (≥0.5 mg/kg IV equivalent) associated with greater benefit.
Source: eClinicalMedicine / The Lancet (2023).
A JAMA Psychiatry meta-analysis comparing ketamine to electroconvulsive therapy (ECT) found ketamine to be non-inferior for treatment-resistant depression, with a more favorable side-effect profile.
Source: JAMA Psychiatry (2022).
Repeated ketamine administration sustains antidepressant benefits beyond single infusion protocols.
Source: Pharmacological Reports (2020).
Comparative evidence suggests IV ketamine and intranasal esketamine (Spravato) have similar short-term efficacy, with IV ketamine showing a slight numerical trend toward better remission and response rates during the induction phase.
Source: Neuropsychopharmacology (2025), systematic review and meta-analysis.
Ketamine for Anxiety, PTSD & Trauma
Post-traumatic stress disorder affects 6–7% of adults at some point in their lives and is frequently resistant to conventional pharmacologic treatments.
Key Research Findings
A randomized controlled trial demonstrated that a single IV ketamine infusion produced rapid reduction in PTSD symptoms compared to midazolam control, measurable within 24 hours.
Source: Feder et al., JAMA Psychiatry (2014).
A 2024 systematic review found ketamine produced improvements comparable to — and in some measures exceeding — FDA-approved PTSD medications, with the added advantage of rapid onset.
Source: Annals of Pharmacotherapy (2024).
Ketamine-assisted psychotherapy (KAP) combined with mindfulness-based exposure therapy showed sustained improvements in clinician-reported PTSD scores.
Source: Asia Pacific Journal of Clinical Trials (2017).
A 2023 neuroimaging study demonstrated structural and functional brain changes after ketamine plus brief exposure therapy.
Source: Neuropsychopharmacology (2023).
University of Florida research (2025) found supervised ketamine helped patients process traumatic experiences by creating a controlled dissociative state.
Source: European Journal of Trauma & Dissociation (2025).
Ketamine for Chronic Pain & Migraine
Chronic pain and migraine affect hundreds of millions worldwide and are often difficult to treat when refractory to standard therapies.
Key Research Findings
A systematic review found 100% of migraine patients without aura experienced acute pain relief after IV ketamine infusion, with significant reductions in chronic migraine pain scores.
Source: Practical Neurology (2023).
Prospective research found ketamine reduced baseline migraine pain significantly and outperformed lidocaine infusions in acute pain reduction.
Source: Observational Pilot Study (2022).
A meta-analysis confirmed ketamine infusions reduce chronic pain severity across multiple conditions.
Source: Anesthesia & Analgesia (2019).
IV ketamine has been used successfully for refractory chronic migraine when standard therapies have been exhausted.
Source: Current Pain and Headache Reports (2021).
Metabolic Psychiatry: The Science of Root-Cause Mental Health
Metabolic psychiatry represents a paradigm shift in understanding mental illness through the lens of cellular energy production, mitochondrial function, inflammation, and glucose metabolism.
Key Research Findings
Research has demonstrated that psychiatric disorders share common metabolic abnormalities, particularly mitochondrial dysfunction affecting ATP production.
Source: Brain Energy (2022); BJPsych Open (2025).
Ketogenic dietary interventions produced significant improvements in psychiatric symptoms and metabolic markers in patients with schizophrenia.
Source: Clinical Nutrition and Metabolism (2018).
Research established that ketogenic diets address glucose hypometabolism, neurotransmitter imbalances, oxidative stress, and inflammation.
Source: Current Opinion in Endocrinology, Diabetes & Obesity (2020).
Studies suggest ketogenic intervention may represent a paradigm shift in bipolar disorder treatment.
Source: BJPsych Open (2025).
Ongoing clinical trials are advancing research connecting metabolism and mental illness.
Source: McLean Hospital (2024).
Epidemiological data shows a bidirectional relationship between metabolic disease and mental illness.
Source: Harvard ALI Social Impact Review (2022).
Neuroplasticity, The Gupta Program & Integration Science
Ketamine creates a neuroplastic window — a temporary period of enhanced brain flexibility and rewiring capacity.
Key Research Findings
The Gupta Program demonstrated significant symptom reduction in fibromyalgia patients in randomized controlled trials.
Source: Journal of Clinical Medicine (2020); PMC (2024).
In a randomized controlled trial for Long COVID, The Gupta Program significantly reduced fatigue and increased energy levels.
Source: Gupta Program RCT (2024).
An international clinical audit across 14 chronic conditions found 73% of participants reported improvement after sustained program use.
Source: AB Research Consulting audit; PMC (2024).
Ketamine-assisted psychotherapy produces more durable outcomes when paired with structured therapeutic work.
Sources: Pradhan et al. (2017); Davis et al. (2022); Harpaz-Rotem et al. (2023).
The neuroplasticity window peaks 24–48 hours following treatment, informing integration protocol design.
Sources: Molecular Psychiatry; Science (2010).
Our Commitment to Ongoing Research
The science of ketamine therapy, metabolic psychiatry, and neuroplasticity-based healing is rapidly evolving.
We update this page as significant new research emerges and remain connected to leading researchers and institutions in the field.
If you are a clinician, researcher, or patient seeking primary literature, we encourage deeper exploration.
Our commitment is simple: evidence first, patient safety always.
Evidence-Based Treatment. Physician-Led Care. Real Results.
Ready to explore whether our approach is right for you?
Medical Disclaimer
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding medical decisions.